Skip to content

Opening book details…

Can I read ISPE MidYear 2021 on EtoBox?

ISPE MidYear 2021 is a Medicine article available to read on EtoBox.

What is ISPE MidYear 2021 about?

Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are the newest class of medications for the management of type-2 diabetes with favorable cardio-and reno-protective effects. However, several case reports raised a concern that their use may increase the risk of acute kidney injury (AKI), which has led to safety warnings by the Food and Drug Administration (FDA) and Health Canada. Objective: In this study, we assessed the association between SGLT2-i exposure and the risk of AKI. Methods: We conducted a population-based cohort study using Alberta's administrative healthcare data and the United Kingdom's Clinical Practice Research Datalink (CPRD). Among new users of metformin monotherapy, multiple new-user cohorts of a second antidiabetic agent were defined based on new use of an SGLT2-i or active antihyperglycemic comparator between 2013-2018. The primary exposure contrast of interest was SGLT2-i versus dipeptidyl peptidase-4 inhibitor (DPP4-i). The outcome was hospitalization due to AKI, identified by validated algorithms based on International Classification of Diseases version 10 codes. The independent association between SGLT2-i use and the risk of developing AKI w

Who reads ISPE MidYear 2021?

It is typically read by researchers, students, and practitioners in Medicine.

Publisher
Wiley
Published
2021
Language
EN
Field
Medicine (Health Sciences)